Indegene is said to be recognized for providing digitally guided commercialization services tailored for the life sciences sector, with a focus on the sales of medical devices, pharmaceuticals, and emerging biotech enterprises, along with product marketing. According to insights from Swastika Investmart, the company has cultivated relationships with all 20 of the world's largest pharmaceutical companies.
Reports indicate that their financial performance reflects consistent growth over the past three fiscal years, supported by a robust client base of 65 active clients as of December 31, 2023. Indegene is noted to have a comprehensive technology portfolio that enhances its digital capabilities. While the P/E valuation is stated to stand at 37.79 times, it is regarded as reasonable, leading analysts to recommend it for long-term investment and potential listing gains.
